The novel compound MP407 inhibits platelet aggregation through cyclic AMP-dependent processes
作者:Chung-Shuen Lin、Tso-Hsiao Chen、I-Hsin Lin、An-Rong Lee、Tz-Chong Chou
DOI:10.1016/j.ejphar.2017.09.024
日期:2017.11
investigated the effects of the new synthesized compound, MP407 on platelet aggregation and further elucidated the underlying mechanisms. Our results demonstrated that MP407 dose-dependently inhibited collagen-induced platelet aggregation, thromboxane B2 (TXB2) production, intracellular Ca2+ mobilization, platelet membrane GPIIb/IIIa expression, and the phosphorylation of Akt, GSK3β, p38MAPK, and phospho
血小板过度活跃对于引发多种血管疾病(如动脉粥样硬化)起着至关重要的作用。因此,开发有效的抗血小板剂对于改善血小板相关疾病是必要的。在这项研究中,我们调查了新合成的化合物MP407对血小板聚集的影响,并进一步阐明了其潜在机制。我们的结果表明MP407剂量依赖性地抑制胶原蛋白诱导的血小板聚集,血栓烷B2(TXB2)产生,细胞内Ca2 +动员,血小板膜GPIIb / IIIa表达以及Akt,GSK3β,p38MAPK和磷酸(Ser)PKC底物的磷酸化(第47页)。此外,MP407能够增加静止和活化血小板中环状AMP的形成。但是,用2'5'-ddAdo阻止循环AMP的形成,腺苷酸环化酶的抑制剂,极大地逆转了MP407的抗血小板活性和相关的血小板活化途径。MP407还增强了胶原蛋白刺激的血小板中Ser157处的VASP磷酸化作用,该作用被添加2'5'-ddAdo减弱。因此,MP407的抗血小板活性可